Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Final 5-year follow-up data from 1,230 patients in the double-blind, U.S. TAXUS IV trial showed that all-cause
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury